Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Annual Covid-19 Vaccine Booster Shots Likely Needed, Pfizer CEO Says -- Update

04/15/2021 | 06:12pm EDT

By Jared S. Hopkins

Pfizer Inc. Chief Executive Albert Bourla said it is likely that people who receive Covid-19 vaccines will need booster shots within a year afterward, and then annual vaccinations, to maintain protection against the virus as it evolves.

"The variants will play a key role. It is extremely important to suppress the pool of people that can be susceptible to the virus," Mr. Bourla said during a virtual event hosted by CVS Health Corp. that aired Thursday but was recorded April 1.

"There are vaccines like polio where one dose is enough," Mr. Bourla said. "And there are vaccines like flu that you need every year. The Covid virus looks more like the influenza virus than the polio virus."

More research is required to confirm the need for annual booster shots, he said. But he added that the need appeared likely given research so far.

The chief executive's comments come as the U.S. and other countries race to vaccinate as many people as possible and try to stay ahead of any variants that could evade the shots.

Researchers still don't know how long protection lasts from any of the Covid-19 vaccines, although they are studying the issue. New shots or boosters might be necessary, vaccine experts say, if the virus mutates significantly enough.

In the rush to introduce vaccines for the new virus, companies and other vaccine researchers didn't have time to determine how long shots would provide protection, or whether booster shots would be needed to ensure protection.

Pfizer and its partner, BioNTech SE, said recently that the shot remains highly effective six months after its second dose, and they hope to provide more information on protection beyond six months in the coming weeks.

Health regulators began authorizing use of Pfizer-BioNTech's shot in December and the vaccine has been rolled out in dozens of countries. Since then, millions of people across the world have been vaccinated.

Mr. Bourla and other Pfizer executives have said since last year that annual or seasonal shots were likely. In February, Pfizer and BioNTech began a study testing in people whether a third dose of the companies' inoculation can protect against emerging variant strains.

Moderna Inc. executives have also said they expect boosters to be needed to ensure protection lasts in vaccinated people. The company recently started studying whether a booster shot of its two-dose vaccine is effective against a variant of the virus.

Countries with high vaccination rates will be ready to shift their focus to boosters possibly at the end of this year, Moderna said during a company vaccine event this week. Moderna President Stephen Hoge said it is safe to assume boosters would be needed "annually, probably seasonally, even though the pandemic is raging in a nonseasonal way."

The Moderna and Pfizer-BioNTech vaccines are based on a new gene-based technology called messenger RNA. The likelihood that periodic Covid-19 shots will be needed is one reason Pfizer executives have said the company plans to expand its vaccine business by becoming a leader in mRNA.

Write to Jared S. Hopkins at jared.hopkins@wsj.com

(END) Dow Jones Newswires

04-15-21 2012ET

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -1.62% 168 Delayed Quote.109.48%
CVS HEALTH CORPORATION 0.79% 83.7 Delayed Quote.21.58%
MODERNA, INC. -1.44% 160.5 Delayed Quote.55.87%
PFIZER, INC. -0.99% 39.19 Delayed Quote.8.53%
All news about PFIZER, INC.
05:48pNACI chair says advice not meant to give AstraZeneca recipients vaccine remor..
05:44pPFIZER  : Canadian athletes, coaches applaud news of vaccine doses ahead of Toky..
05:22pHealth Care Down On Vaccine Patent Waiver Fears -- Health Care Roundup
05:11pWALL STREET STOCK EXCHANGE : Stocks Stage Late Rally; Dow Hits Record
04:11pEU supports COVID vaccine patent waiver talks, but critics say won't solve sc..
02:17pWALL STREET STOCK EXCHANGE : Stocks Close Higher As Tech Shares Rebound, Dow Hit..
01:24pStocks Rise in Choppy Trade as Jobless Claims Fall, Dallas Fed Chief Favors D..
12:52pPFIZER  : Vatican conference features Fauci, Francis — and Aerosmith
12:14pBIONTECH  : Says Patents 'Not Limiting Factor' for Vaccine Production, Supply
12:01pNOVOTEK AB : Kommuniké från årsstämma
More news
Financials (USD)
Sales 2021 69 466 M - -
Net income 2021 17 545 M - -
Net Debt 2021 27 786 M - -
P/E ratio 2021 14,2x
Yield 2021 3,96%
Capitalization 223 B 223 B -
EV / Sales 2021 3,61x
EV / Sales 2022 4,29x
Nbr of Employees 78 500
Free-Float 59,0%
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 24
Average target price 41,65 $
Last Close Price 39,97 $
Spread / Highest target 32,6%
Spread / Average Target 4,19%
Spread / Lowest Target -9,93%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER, INC.8.53%222 959
JOHNSON & JOHNSON6.16%439 961
ROCHE HOLDING AG-2.98%283 498
ABBVIE INC.8.05%204 332
MERCK & CO., INC.-5.01%196 682
NOVARTIS AG-5.70%193 868